Vertex Pharmaceuticals (VRTX) Stock Looks Cheap Next To Its Cash Flow

Simply Wall St.11-05

Vertex Pharmaceuticals has ridden a long winning streak in the market over the past five years, and fresh clinical and revenue headlines keep attention on the story. The live question for investors is...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681076957?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256","is_english":true,"pubTime":"2026-11-05 21:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681076957","market":"us","top_or_hot":-1,"title":"Vertex Pharmaceuticals (VRTX) Stock Looks Cheap Next To Its Cash Flow","media":"Simply Wall St.","content":"<div>\n<p>Vertex Pharmaceuticals has ridden a long winning streak in the market over the past five years, and fresh clinical and revenue headlines keep attention on the story. The live question for investors is...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-looks-cheap-next-to-its-ca\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Pharmaceuticals (VRTX) Stock Looks Cheap Next To Its Cash Flow</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Pharmaceuticals (VRTX) Stock Looks Cheap Next To Its Cash Flow\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-05 21:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-looks-cheap-next-to-its-ca><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vertex Pharmaceuticals has ridden a long winning streak in the market over the past five years, and fresh clinical and revenue headlines keep attention on the story. The live question for investors is...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-looks-cheap-next-to-its-ca\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-looks-cheap-next-to-its-ca","article_id":"2681076957","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-stock-looks-cheap-next-to-its-ca","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681076957","pubTimestamp":1793885526,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 5, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BIB":"Ultra纳斯达克生物科","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IBB":"生物科技指数ETF-iShares Nasdaq","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","GNMX":"Corgi Genomics & Precision Medicine ETF","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IDNA":"iShares Genomics Immunology and Healthcare ETF","BK4023":"应用软件","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","VERX":"Vertex, Inc.","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BBH":"VanEck Biotech ETF","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","VRTX":"福泰制药"},"translate_title":"Vertex Pharmaceuticals (VRTX) 的股票与其现金流相比看起来很便宜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERX":1.5,"TBXU":0.6,"VRTX":1.5,"IBB":0.6,"GNMX":0.6,"PBE":0.6,"BIB":0.6,"IDNA":0.6,"DCF":1,"BBH":0.6,"IBBQ":0.6},"content_text":"Vertex Pharmaceuticals has ridden a long winning streak in the market over the past five years, and fresh clinical and revenue headlines keep attention on the story. The live question for investors is whether the current share price lines up with what the company’s cash flows can justify over time.  Over the past 5 years, Vertex Pharmaceuticals has delivered a 192.2% share price return, which puts a lot of weight on whether its underlying cash generation can keep backing that kind of move. Recent positive trial results for povetacicept in IgA nephropathy and stronger reported revenue from its cystic fibrosis and acquired therapies can influence how investors think about future cash flows, especially the timing and durability of potential new treatment contributions. If you'd rather focus on earnings, this one's for you. See why Vertex Pharmaceuticals's 35.0x P/E tells a different valuation story.  The stock’s next move may depend on whether a Discounted Cash Flow (DCF) view of Vertex Pharmaceuticals suggests that today’s price is fully supported by the cash the business is expected to produce. If you want more than a single case study, a focused stock screen is a clean way to widen your watchlist using 35 high quality undervalued stocks. AdvertisementDoes Vertex Pharmaceuticals Look Undervalued on Cash Flow? The Discounted Cash Flow (DCF) model here is built around Vertex Pharmaceuticals’ ability to keep generating and growing free cash. Over the last twelve months the business produced about $3.17b in free cash flow, and the 2 Stage Free Cash Flow to Equity model assumes that this figure grows over time rather than shrinking. Projected cash flows in the model rise into the next decade, and when these are discounted back they point to an estimated intrinsic value that sits substantially above the current share price of $549.04. Because the recent positive Phase 3 RAINIER results for povetacicept in IgA nephropathy reinforce expectations for future treatment revenue, that kind of pipeline progress helps explain why the cash flow view comes out ahead of where the stock trades today. Find out what Vertex Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate. The Vertex Pharmaceuticals Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where the Vertex Pharmaceuticals valuation puzzle leaves off. Narratives spell out what would need to happen to the company’s future growth, profitability and earnings path for the stock to look meaningfully higher or lower than today’s price. Each one ties a fair value estimate to a specific mix of potential catalysts and risks so you can track which storyline appears to be unfolding over time on the Community page. Vertex Pharmaceuticals splits the community, with one camp seeing plenty left in the story and another arguing expectations already look full. Bull case: roughly fairly valued \"Vertex Pharmaceuticals is building a broader portfolio beyond cystic fibrosis, with management expecting non CF products such as CASGEVY and JOURNAVX to contribute at least US$0.5b of 2026 revenue...\" Discover why this Narrative puts Vertex Pharmaceuticals at roughly fairly valued. Bear case: 27% overvalued \"Bearish analysts expect Vertex Pharmaceuticals to face ongoing margin pressure as patient support and pricing dynamics in products like JOURNAVX delay full revenue realization from prescription growth...\" Explore why this Narrative puts Vertex Pharmaceuticals at 27% overvalued. One more Vertex Pharmaceuticals question that could change how you see the story Cash flows and clinical progress only go so far if the people calling the shots are not aligned with you. It is worth checking who sits in the key seats, how they are rewarded, and what that might encourage them to prioritise. See who runs Vertex Pharmaceuticals and how they are paid. This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681076957","isCrawlerRequest":true}